

Review Article**Cardiovascular Diseases: A Molecular Diagnostic Approach**

Nigam.N ,Mishra.A, Nigam.S ,Lalchandani.D.A

Abstract

The findings of various studies have led to the conclusion that multifactorial diseases such as hypertension, diabetes, cardiovascular diseases, obesity etc are also controlled at genetic level with respect to the environmental factors. Cardiovascular disease is the major cause of morbidity and mortality in Westernized societies. It is well known that the etiology of this devastating disorder involves both genetic and environmental factors. Sequence variants of the components of the renin-angiotensin-aldosterone system suggested to have significant influences on cardiovascular homeostasis. Polymorphisms of the genes encoding Angiotensin-1 converting enzyme, MTHFR and VDR represent an area of intense research for cardiovascular disease associations, with promising, although sometimes contradictory findings.

Key Words- Cardiovascular Disease, ACE1, MTHFR, VDR, polymorphism

Introduction

The global burden of cardiovascular disease is increasing as the world's population ages and the lifestyle in lower and middle income countries become more similar to wealthier nations [1]. Cardiovascular diseases(CVDs) are a group of disorders of the heart and blood vessels and they include coronary heart diseases, peripheral arterial diseases, congenital heart diseases etc. The concept of cardiovascular risk continuum was first proposed by Dzau and Braunwald as a new paradigm for cardiovascular disease pathogenesis [2]. Modifiable risk factors of cardiovascular disease such as hypertension, abdominal obesity, abnormal lipids, smoking, diabetes mellitus as well as stress, low consumption of fruits and vegetables and lack of regular physical activity are the important risk factors and contribute to >90% of all myocardial infarctions[3]. Cardiovascular risk factors show a continuous association with overall cardiovascular risk with no minimum threshold for disease [4]. Risk factors rarely occur in isolation and instead tend to cluster in individuals. The risk factors act synergistically to increase the cardiovascular disease risk by multiple times[5]. Today over 80% of the world's death occur from CVDs. According to the facts of WHO (World Health Organization) CVDs are the number one causes of death globally: more people die annually from CVDs than from any other cause. An estimated 17.3 million people die from CVD in 2008, representing 30% of all global deaths. The The number of people who died from CVDs mainly heart diseases and stroke will increase to reach 23.3 million by 2030. 9.4 million deaths each year or 16.5% of all deaths can be attributed to high

blood pressure. CVDs are projected to remain the single leading cause of death.

Researchers have identified more than 250 genes that play role in CVDs. As we know that CVD often results from the blended effects of multiple genes known as polygenic effects mean that the genetics of CVD are extremely complicated, with many different genes influencing a person's risk.

Angiotensin-1 converting enzyme (ACE) gene: A Major culprit in Cardiovascular diseases:

Polymorphism at intron 16 of the angiotensin-1 converting enzyme (ACE) gene, located at chromosome 17q23, has been implicated in various disease etiologies, including coronary artery disease[6], myocardial infarction [7], left ventricular hypertrophy [8], diabetes [9], hypertension[10],venous thrombosis [11], diabetic nephropathy [12], coronary restenosis [13], Alzheimer [14], and ischemic stroke [15], and in a number of such physiological events such as athletic mechanical efficiency and in performance endurance [16, 17] and in senescence [18]. However, other studies have suggested that there is no association of disease etiology with ACE I/D gene polymorphism [19-23]. The ACE polymorphism identified in 1990 by Rigat and co-workers is one of the best-researched polymorphisms. This polymorphism of the ACE gene is based on the presence or absence of a 287-bp element on intron 16 on chromosome 17. Rigat et al.[24] have shown that the level of circulating ACE enzymes depends on the insertion/ deletion (I/D) polymorphism. Angiotensin I-converting enzyme (ACE, CD143, EC 3.4.15.1), a zinc-metalloproteinase, is a key regulator of blood pressure participating in the development of vascular pathology and remodeling[25-27]. ANGIOTENSIN-converting enzyme (EC 3.4.15.1; dipeptidyl carboxypeptidase) is

a zinc metallopeptidase which cleaves the C-terminal dipeptide (His–Leu) from angiotensin 1 and generates a vasoconstrictor[28], angiotensin II. Through protease activity it also inactivates bradykinin, which is a potent vasodilator. Due to its role in the renin-angiotensin–aldosterone system, human vascular tone and blood salt/water balance have been maintained. The gene for angiotensin converting enzyme (ACE) comprises 26 exons and 25 introns[29-30]. The activity of ACE was strongly influenced by a quantitative trait locus which is in linkage disequilibrium with the *Alu* insertion/deletion (I/D) marker [24, 31-33] in intron 16. A relationship between D-allele dose and enzymatic levels was established for both circulating and cellular ACE [34-39]. Numerous studies reported association of D-allele with cardiovascular diseases [40-43]. However, this association was not observed in all the studies[44-49]. Thus, there has been a considerable controversy over the association of ACE (I/D) polymorphism and disease status. The insertion deletion (I/D) polymorphism in this gene refers to an *Alu* repetitive sequence 287 bp long, in intron 16, resulting in three genotypes, *DD* and *II* homozygotes and *ID* heterozygotes. The *ID* polymorphism is reported to determine circulating and tissue *ACE* levels, such that individuals homozygous for the *D* allele have higher tissue and plasma *ACE* concentrations than heterozygotes and *II* homozygotes [24,50]. The *ID* polymorphism is associated with cardiovascular diseases [51-54] as well as chronic renal diseases[55,56]. The *DD* genotype is known as an independent risk factor in several cardiovascular diseases such as hypertrophic cardiomyopathy[52], myocardial infarction [51, 54] and ventricular hypertrophy [53], as well as chronic renal diseases such as IgA nephropathy [57], diabetic nephropathy [58], renal scarring [59; 56,60] and congenital urological anomalies [55] *Alu* insertion polymorphisms, like *ACE* I/D polymorphism, are also suitable markers for studying genetic variation in human populations. They can be easily detected by PCR amplification and gel electrophoresis and they are stable markers that represent a unique evolutionary event. The distribution of the *ACE* genotypes differs between races and it is used as a marker in population structure analyses [61].

MTHFR gene: Candidate gene polymorphism in Cardiovascular diseases

About 30 years ago, McCully postulated that mildly elevated homocysteine concentrations could increase the risk of cardiovascular disease[62] after observing artery wall lesions in two different metabolic disorders of methionine metabolism which resulted in

elevated plasma homocysteine concentrations[63]. Since then many studies have been conducted to investigate whether elevated plasma homocysteine concentrations are associated with an increased risk of cardiovascular disease. A modest elevation of plasma homocysteine concentration, commonly referred to as hyperhomocysteinaemia, is generally[64, 65] although not universally[66, 67] accepted as an independent and graded risk factor for both arterial occlusive diseases and venous thrombosis[68, 69]. In 1988, Kang *et al.*[70] detected a variant of the MTHFR enzyme which was associated with decreased enzyme activity, reduced stability after heating at 46°C and increased homocysteine concentrations. A few years later these authors demonstrated that this thermolabile form of the MTHFR enzyme was more common among CVD patients (17%) than among controls (5%)[71]. In many studies this thermolabile MTHFR enzyme was identified in patients with different forms of premature vascular disease and was associated with fasting as well as post-methionine-load homocysteine concentrations[72]. In 1995, Frosst *et al.*[73] identified the single base pair substitution of C to T at nucleotide 677 to be responsible for this thermolabile MTHFR enzyme. Since then, numerous studies have been reported which investigated this MTHFR variant and its association with homocysteine concentrations and CVD risk [74]. Although an association between the 677C !T variant and elevated homocysteine concentrations was universally found[75,76,73] an increased risk for CVD was found in only some studies[75, 76]. The association between the 677C! T variant and elevated homocysteine concentrations was reported to exist only in individuals with low folate status[78,79]. In 1998, the hypothesis that this variant is associated with altered distribution of RBC folates was tested by a chromatographic method *in vitro* [84]. This method involves the analysis of RBC folates by affinity/high-performance liquid chromatography with electrochemical (coulometric) detection [85]. Probably due to the reduced MTHFR enzyme activity, formylated tetrahydrofolate polyglutamates were present at the expense of methyl-THF in most 677TT individuals. Thermolabile MTHFR accounts for 25% of the mild hyperhomocysteinaemia observed in patients with vascular disease [72], indicating that additional mutations in the MTHFR gene or other genes may also affect homocysteine concentrations. Moreover, it appears that the 677TT genotype is associated with increased homocysteine concentrations only in individuals with low folate status [78,79]. Thus, possible gene-environment interactions also play an important role in modulating plasma homocysteine

concentrations. In 1998, a second common polymorphism in the MTHFR gene was described, the 1298A!C transition, which mandates an amino acid substitution of glutamate by alanine [86]. This variant was observed only in *trans* with the 677C!T variant and was associated with decreased MTHFR enzyme activity. We have described the associations of this 1298A!C variant with MTHFR enzyme activity, plasma homocysteine concentrations and risk of CVD [87]. We again detected a decrease in enzyme activity in individuals with the 1298AC and 1298CC genotypes, but noted no effect on the thermostability of the enzyme or on plasma homocysteine concentrations. Although all studies confirm that the 1298A!C variant is associated with decreased MTHFR activity [86-89] supported by expression analysis in *Escherichia coli* [90] an association with homocysteine concentrations has not been detected [88,89,91-96]. Probably, other factors that affect homocysteine concentrations, such as nutritional status, play a role, or the decreased MTHFR enzyme activity must reach a certain threshold below which increased plasma homocysteine concentrations result.

VDR gene polymorphism in Cardiovascular diseases

The active form of vitamin D, 1,25 dihydroxyvitamin D or calcitriol, is the end product of two hydroxylation steps of vitamin D: a hepatic 25-hydroxylation and a subsequent renal 1 α -hydroxylation. Calcitriol exerts genomic and non genomic effects through a cytosolic vitamin D receptor (VDR) and a membrane bound receptor. VDRs have been found in almost all human tissues and cells, among them cardiomyocytes, endothelial cells, and vascular smooth muscle cells. Several tissues also possess an enzymatically active 25-hydroxyvitamin D-1 α -hydroxylase system, among them vascular smooth muscle cells [97]. Studies have revealed that the biologically active metabolite of vitamin D—1,25 dihydroxy-vitamin D (1,25[OH]₂D)—can modulate various processes involved in the pathogenesis of cardiovascular disease (CVD) through its role in calcium homeostasis and through the participation of its receptor—a steroid hormone nuclear receptor—in the regulation of gene transcription. Its effects appear to support normal myocardial contractility, vasomotor activity, and nitric oxide production, while reducing the risk of cardiac hypertrophy and atherosclerosis. Thus, vitamin D may be beneficial in patients with heart failure, arrhythmias, ischemic heart disease, or hypertension. Briefly, it is a steroid hormone whose

primary function is to maintain calcium homeostasis by enhancing calcium absorption from the intestinal tract, promoting osteoblast differentiation, and inhibiting osteoclast activity. By supporting calcium homeostasis, vitamin D inhibits substances that are activated by low serum calcium levels—including parathyroid hormone (PTH)—most of which promote bone resorption as a means of restoring normal calcium levels. Its biologically active metabolite, 1,25 dihydroxy-vitamin D (1,25[OH]₂D), binds with the vitamin D receptor (VDR), a steroid hormone nuclear receptor that participates in the regulation of gene transcription. Because of the virtually ubiquitous nature of the VDR, vitamin D can affect a myriad of functions in body tissues, including intracellular signaling pathways that block cell proliferation, promote cell differentiation, modulate immune activity, and influence blood pressure (BP). Its potential cardiovascular benefits are associated with its ability to inhibit PTH, which is involved in the pathogenesis of several conditions that increase the risk for heart disease (HD). This study will elucidate the role of VDR gene polymorphism in cardiovascular patients. It is found that genetic variants in VDR gene were associated with an increased risk for stroke and other myocardial infarction especially in Vitamin D deficient subjects. This finding could contribute to the development of strategies for the prevention of cardiovascular diseases [98,99].

Conclusion

Although there are several mendelian disorders that contribute to CVD, most common forms of CVD are believed to be multifactorial and to result from many genes, each with a relatively small effect working alone or in combination with modifier genes and/or environmental factors. The identification and the characterization of these genes and their modifiers would enhance prediction of CVD risk and improve prevention, treatment, and quality of care. This scientific statement describes the approaches researchers are using to advance understanding of the genetic basis of CVD and details the current state of knowledge regarding the genetics of myocardial infarction, atherosclerotic CVD, hypercholesterolemia, and hypertension

References

1. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liao CS, Richard AJ, Röther J, Wilson PW; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. *JAMA* 2006;295(2):180-9.

2. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. *Am Heart J* 1991;121:1244-63.
3. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). *Circulation*. 2006;114(25):2850-70.
4. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). *JAMA* 28;256(20):2823-8.
5. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. *Lancet* 2005;365(9455):217-23.
6. Seckin D, Ilhan N, Ilhan N, Ozbay Y. The relationship between ACE insertion/deletion polymorphism and coronary artery disease with or without myocardial infarction. *Clin Biochem* 2006; 39: 50-4.
7. Araujo MA, Goulart LR, Cordeiro ER, et al. Genotypic interactions of renin-angiotensin system genes in myocardial infarction. *Int J Cardiol* 2005; 103: 27-32.
8. Saeed M, Saleheen D, Siddiqui S, Khan A, Butt ZA, Frossard PM. Association of angiotensin converting enzyme gene polymorphisms with left ventricular hypertrophy. *Hypertens Res* 2005; 28: 345-9.
9. Daimon M, Oizumi T, Saitoh T, et al. The D allele of the angiotensin-converting enzyme insertion / deletion (I/D) polymorphism is a risk factor for type 2 diabetes in a population-based Japanese sample. *Endocrine J* 2003; 50: 393-8.
10. Zee RY, Lou YK, Griffiths LR, Morris BJ. Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. *Biochem Biophys Res Comm* 1992; 184: 9-15.
11. Fatini C, Gensini F, Sticchi E, et al. ACE DD genotype: an independent predisposition factor to venous thromboembolism. *Eur J Clin Invest* 2003; 33: 642-7
12. Movva S, Alluric RV, Komandur S, et al. Relationship of angiotensin-converting enzyme gene polymorphism with nephropathy associated with Type 2 diabetes mellitus in Asian Indians. *J Diabetes Complications* 2007; 21: 237-41
13. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme. A major risk factor and a marker of risk for coronary stent restenosis. *Circulation* 1998; 97: 147-54
14. Wang B, Jin F, Yang Z, et al. The insertion polymorphism in angiotensin-converting enzyme gene associated with the APOE epsilon 4 allele increases the risk of late-onset Alzheimer disease. *J Mol Neurosci* 2006; 30: 267-71
15. Tseng CH, Tseng CP, Chong CK, Sheu JJ, Cheng JC. Angiotensin-converting enzyme gene polymorphism and stroke in type 2 diabetic patients in Taiwan. *Eur J Clin Invest* 2007; 37: 483-91.
16. Williams AG, Rayson MP, Jubb M, et al. The ACE gene and muscle performance. *Nature* 2000; 403: 614.;
17. Amir O, Amir R, Yamin C, et al. The ACE deletion allele is associated with Israeli elite endurance athletes. *Exp Physiol* 2007; 92: 881-6.
18. Schachter F, Faure-Delanef L, Guenot F, et al. Genetic associations with human longevity at the APOE and ACE loci. *Nature Genet* 1994; 6: 29-32.
19. Schmidt S, Schone N, Ritz E, et al. Association of ACE gene polymorphism and diabetic nephropathy? *Kidney Int* 1995; 47: 1176-81.;
20. Agerholm-Larsen B, Tybjaerg-Hansen A, Frikke-Schmidt R, Gronholdt MLM, Jensen G, Nordestgaard BG. ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease. *Ann Intern Med* 1997; 127: 346-55.;
21. Clark CJ, Davies E, Anderson NH, et al. α -Adducin and ACE polymorphism in essential hypertension. *Hypertension* 2000; 36: 990-4.
22. Moleda P, Majkowska L, Kaliszczak R, Safranow K, Adler G, Goracy I. Insertion/deletion polymorphism of angiotensin I converting enzyme gene and left ventricular hypertrophy in patients with type 2 diabetes mellitus. *Kardiologia Pol* 2006; 64: 959-65
23. Nacmias B, Bagnoli S, Tedde A, et al. Angiotensin converting enzyme insertion/deletion polymorphism in sporadic and familial Alzheimer's disease and longevity. *Arch Gerontol Geriatr* 2007; 45: 201-6.;
24. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of

- serum enzyme levels. *J Clin Invest* 1990, 86:1343–1346.
25. Ehlers MWR, Riordan JF (1989) Angiotensin-converting enzyme: new concepts concerning its biological role. *Biochemistry* 8: 5311–5318.
 26. Bernstein KE, Xiao HD, Frenzel K, Li P, Shen XZ, et al. (2005) Six truisms concerning ACE and the renin-angiotensin system deduced from the genetic analysis of mice. *Circ Res* 96: 1135–1144.
 27. Sturrock ED, Anthony CS, Danilov SM (2012) Peptidyl-dipeptidase A/ Angiotensin I-converting enzyme. In: Editors-in-Chief: Neil D. Rawlings, Guy Salvesen, *Handbook of Proteolytic Enzymes*, 3rd Edition, Academic Press, Oxford (in pres).
 28. Davis, G. K. and Roberts, D. H., Molecular genetics of the renin–angiotensin system: Implications for angiotensin II receptor blockage. *Pharmacol. Ther.*, 1997, **75**, 43–50.
 29. Mattei, M. G., Hubert, C., Alhenc-Gelas, F., Roeckel, N., Corvol, P. and Soubrier, F., Angiotensin I converting enzyme gene is on chromosome 17. *Cytogenet. Cell. Genet.*, 1989, **51**, 1041–1045.
 30. Hubert, C., Houot, A. M., Corvol, P. and Soubrier, F., Structure of the angiotensin I converting enzyme gene. Two alternative promoters correspond to evolutionary steps to a duplicated gene. *J. Biol. Chem.*, 1991, **266**, 15377–15383.
 31. Cambien, F. et al., Familial resemblance of plasma angiotensin converting enzyme level: The Nancy study. *Am. J. Hum. Genet.*, 1988, **43**, 774–780
 32. Rieder, M. J., Taylor, S. L., Clark, A. G. and Nickerson, D. A., Sequence variation in the human angiotensin converting enzyme. *Nature Genet.*, 1999, **22**, 59–62.
 33. Rigat, B., Hubert, C., Corvol, P. and Soubrier, F., PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP-1) (dipeptidyl carboxypeptidase 1). *Nucleic Acids Res.*, 1992, **20**, 1433.
 34. Tiret, L., Rigat, B., Visvikis, S., Breda, C., Corvol, P., Cambien, F. and Soubrier, F., Evidence from combined segregation and linkage analysis that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. *Am. J. Hum. Genet.*, 1992, **51**, 197–205.
 35. Ribichini, F. et al., Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme. A major risk factor and a marker of risk for coronary stent restenosis. *Circulation*, 1998, **97**, 147–154.
 36. Malik, F. S., Lavie, C. J., Mehra, M. R., Milani, R. V. and Re, R. N., Renin–angiotensin system: Genes to bedside. *Am. Heart J.*, 1997, **134**, 514–527.
 37. Costerousse, O., Allegrini, J., Lopez, M. and Alhenc-Gelas, F., Angiotensin I converting enzyme in human circulating mononuclear cells: Genetic polymorphism of expression in T-lymphocytes. *Biochem. J.*, 1993, **290**, 33–40.
 38. Marre, M. et al., Relationship between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. *Diabetes*, 1994, **43**, 384–388.
 39. Ohmichi, N., Iwai, N., Uchida, Y., Shichiri, G., Nakamura, Y. and Kinoshita, M., Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. *Am. J. Hypertens.*, 1997, **10**, 951–955.
 40. Danser, A. H., Schalekamp, M. A., Bax, W. A., Vanden-Brink, A. M., Saxena, P. R., Rigger, G. A. and Sehunkert, H., Effect of deletion/insertion polymorphism. *Circulation*, 1995, **92**, 1387–1388.
 41. Huang, W., Xie, C., Zhou, H., Yang, T. and Sun, M., Association of the angiotensin-converting enzyme gene polymorphism with chronic heart failure in Chinese Han patients. *Eur. J. Heart Failure*, 2004, **6**, 23–27
 42. Reynolds, M. V. et al., Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. *Lancet*, 1993, **342**, 1073–1075.
 43. Andersson, B., Blange, I. and Sylven, C., Angiotensin-type I receptor gene polymorphism and long-term survival in patients with idiopathic chronic heart failure. *Eur. J. Heart Failure*, 1999, **1**, 363–369.
 44. Lindpaintner, K. et al., A prospective evaluation of an angiotensin converting enzyme gene polymorphism and the risk of ischaemic heart disease. *N. Engl. J. Med.*, 1995, **332**, 706–711.
 45. Jeunemaitre, X. et al., Genetic polymorphisms of the renin–angiotensin system and angiographic extent and severity of coronary artery disease: The CORGENE study. *Hum. Genet.*, 1997, **99**, 66–73.
 46. Agerholm-Larsen, B., Tybjaerg-Hansen, A., Frikke-Schmidt, R., Gronholdt, M. L. M., Jensen, G. and Nordestgaard, B. G., ACE gene polymorphism as a risk factor for ischaemic cerebrovascular disease. *Ann. Intern. Med.*, 1997, **127**, 346–355.

47. Agerholm-Larsen, B., Nordestgaard, B. G., Steffensen, R., Sorensen, T. I. A., Jensen, G. and Tybjaerg-Hansen, A., Ischaemic heart disease and longevity in 10,15-individuals: A case referent and retrospective cohort study based on the Copenhagen City heart study. *Circulation*, 1997, **95**, 2358–2367.
48. Agerholm-Larsen, B., Nordestgaard, B. G. and Tybjaerg-Hansen, A., ACE gene polymorphism in cardiovascular disease. Metaanalysis of small and large studies in whites. *Arterioscler. Thromb. Vasc. Biol.*, 2000, **20**, 484–492.
49. Schieffer, B. and Drexler, H., ACE gene polymorphism and coronary artery disease. A question of persuasion of statistical confusion? *Arterioscler. Thromb. Vasc. Biol.*, 2000, **20**, 281–282.]
50. Costerousse O., Allegrini J., Lopez M. and Alhenc-Gelas F.1993Angiotensin I converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in Tlymphocytes. *Biochem. J.* 290, 33–40.
51. Cambien F., Poirier O., Lecerf L., Evans A., Cambou J., Arveiler D. et al. 1992 Deletion polymorphism in the gene of angiotensin converting enzyme is a potent risk factor for myocardial infraction. *Nature* 359, 641–644.
52. Marian A., Yu Q., Workman R., Greve G. and Roberts R. 1993 Angiotensin converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. *Lancet* 342, 1085–1086.
53. Schunkert H., Hense H.-W., Holmer S.-R., StenderM., Perz S., Keil U. et al. 1994 Association between a deletion polymorphism of the angiotensin converting enzyme gene and left ventricular hypertrophy. *N. Engl. J. Med.* 330, 1634–1638.
54. Kario K., Kanai N., Saito K., Nago N., Matsuo T. and Shimada K. 1996 Ischemic stroke and the gene for angiotensin converting enzyme in Japanese hypertensives. *Circulation* 93, 1630–1633.
55. Hohenfellner K., Wingen A.-M., Nauroth O., Wuhl E., Mehls O. and Schaefer F. 2001 Impact of ACE I/D polymorphism on congenital renal malformations. *Pediatr. Nephrol.* 16, 356–361.
56. Ohtomo Y., Nagaoka R., Kaneko K., Fukuda Y., Miyano T. and Yamashiro Y. 2001 Ang iotensin converting enzyme gene polymorphism in primary vesicoureteral reflux. *Pediatr. Nephrol.* 16, 648–652.
57. Yoshida H., Mitarai T., Kawamura T., Kitajima T., Miyazaki Y., Nagasawa R. et al. 1995 Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. *J. Clin. Invest.* 96,2162–2169.
58. Doria A., Warram J.-H. and Krolewski A.-S. 1994 Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I-converting enzyme gene. *Diabetes* 43, 690–695.
59. Ozen S., Alikasifoglu M., Saatci U., Bakkaloglu A., Besbas N., Kara N. et al. 1999 Implications of certain genetic polymorphisms in scarring in vesicoureteric reflux: importance of ACE polymorphism. *Am. J. Kidney Dis.* 34, 140–145.
60. Erdogan H., Mir S., Serdaroglu E., Berdeli A. and Aksu N. 2004 Is ACE gene polymorphism a risk factor for renal scarring with low grade reflux? *Pediatr. Nephrol.* 19, 734–737.
61. Barbalic M., Pericic M., Skaric-Juric T. and Smolej-Narancic N. 2004 ACE alu insertion polymorphism in Croatia and its isolates. *Coll. Antropologica* 28, 603–61.
62. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. *Atherosclerosis* 1975; 22: 215-27.
63. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. *Am J Pathol* 1969; 56: 111-28.
64. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. *Arch Intern Med* 1998; 158: 862-7.
65. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. *Am J Clin Nutr* 2000; 72: 324-32.
66. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 1998; 98: 204-10.
67. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect? *Am J Clin Nutr* 2000; 72: 315-23.
68. Den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. *N Engl J Med* 1996; 334: 759-62.
69. Den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. *Thromb Haemost* 1998; 80: 874-.

70. Kang S-S, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. *Am J Hum Genet* 1988; **43**: 414-21.
71. Kang S-S, Wong PWK, Susmano A, Sora H, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. *Am J Hum Genet* 1991; **48**: 536-45.
72. Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. *Am J Hum Genet* 1995; **56**: 142-50.
73. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet* 1995; **10**: 111-3.
74. Fletcher O, Kessling AM. MTHFR association with arteriosclerotic vascular disease? *Hum Genet* 1998; **103**: 11-21.
75. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. *Am J Hum Genet* 1996; **58**: 35-41.
76. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. *Circulation* 1996; **94**: 2154-8.
77. Van der Put NMJ, Steegers-Theunissen RPM, Frosst P, Trijbels FJM, Eskes TKAB, van den Heuvel LP, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bi. da. *Lancet* 1995; **346**: 1070-1.
78. Jacques PF, Bostom AG, Williams RR, Curtis Ellison R, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. *Circulation* 1996; **93**: 7-9.
79. Harmon DL, Woodside JV, Yarnell JW, McMaster D, Young IS, McCrum EE, et al. The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia. *QJM* 1996; **89**: 571-7.
80. Van der Put NM, van den Heuvel LP, Steegers-Theunissen RP, Trijbels FJ, Eskes TK, Mariman EC, et al. Decreased methylene tetrahydrofolate reductase activity due to the 677C!T mutation in families with spina bi. da offspring. *J Mol Med* 1996; **74**: 691-4.
81. Verhoef P, Kok FJ, Kluijtmans LA, Blom HJ, Refsum H, Ueland PM, et al. The 677C!T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. *Atherosclerosis* 1997; **132**: 105-13.
82. Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. *Blood* 1998; **91**: 4158-63.
83. Tsai MY, Bignell M, Yang F, Welge BG, Graham KJ, Hanson NQ. Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine beta-synthase and A(2756)G of methionine synthase, with lowered plasma homocysteine levels. *Atherosclerosis* 2000; **149**: 131-7.
84. Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. *Proc Natl Acad Sci USA* 1998; **95**: 13217-20.
85. Bagley PJ, Selhub J. Analysis of folates using combined af. Nity and ion-pair chromatography. *Methods Enzymol* 1997; **281**: 16-25.
86. Van der Put NMJ, Gabreels F, Stevens EMB, Smeitink JAM, Trijbels FJM, Eskes TKAB, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? *Am J Hum Genet* 1998; **62**: 1044-51.
87. Lievers KJ, Boers GH, Verhoef P, den Heijer M, Kluijtmans LA, van der Put NM, et al. A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk. *J Mol Med* 2001; **79**: 522-8.
88. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. *Mol GenetMetab* 1998; **64**: 169-72.
89. Chango A, Boisson F, Barbe F, Quilliot D, Drosch S, P. ster M, et al. The effect of 677C!T and 1298A!C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase

- activity in healthy subjects. *Br J Nutr* 2000; **83**: 593-6
90. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis ER, et al. The 1298A/C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. *Atherosclerosis* 2001; **156**: 409-15
 91. Friedman G, Goldschmidt N, Friedlander Y, Ben-Yehuda A, Selhub J, Babaey S, et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. *J Nutr* 1999; **129**: 1656-61.
 92. Hanson NQ, Aras O, Yang F, Tsai MY. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. *Clin Chem* 2001; **47**: 661-6.
 93. Dekou V, Whincup P, Papacosta O, Ebrahim S, Lennon L, Ueland PM, et al. The effect of the C677T and A1298C polymorphisms in the methylenetetrahydrofolate reductase gene on homocysteine levels in elderly men and women from the British regional heart study. *Atherosclerosis* 1998; **154**: 659-66.
 94. Fodinger M, Buchmayer H, Heinz G, Papagiannopoulos M, Kletzmayer J, Perschl A, et al. Association of two MTHFR polymorphisms with total homocysteine plasma levels in dialysis patients. *Am J Kidney Dis* 2001; **38**: 77-84.
 95. Meisel C, Cascorbi I, Gerloff T, Stangl V, Laule M, Muller JM, et al. Identification of six methylenetetrahydrofolate reductase (MTHFR) genotypes resulting from common polymorphisms: impact on plasma homocysteine levels and development of coronary artery disease. *Atherosclerosis* 2001; **154**: 651-8.
 96. Szczeklik A, Sanak M, Jankowski M, Dropinski J, Czachor R, Musial J, et al. Mutation A1298C of methylenetetrahydrofolate reductase: risk for early coronary disease not associated with hyperhomocysteinemia. *Am J Med Genet* 2001; **101**: 36-9.
 97. Somjen D, Weisman Y, Kohen F, et al. 25-hydroxyvitamin D3-1 α -hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. *Circulation* 2005; **111**:1666–1671.
 98. Pilz S, Tomaschitz A et al. Vitamin D, cardiovascular disease and mortality. *Clinical Endocrinology* (2011) **75**, 575–584.
 99. Subba Reddy Vanga, Mathew Good, Patricia A., James L. Vacek. Role of Vitamin D in Cardiovascular Health. *Am J Cardiol* 2010; **106**:798–805